- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | Zeo ScientifiX, Inc.: ZEO ScientifiX Plans Expansion into Georgia and Tennessee as New Regenerative Medicine Laws Take Effect | 8.677 | ACCESS Newswire | Company looks to broaden its Southeast presence to support healthcare providers navigating newly enacted state laws providing for certain stem cell and regenerative medicine therapies. FORT LAUDERDALE... ► Artikel lesen | |
| ZEO SCIENTIFIX Aktie jetzt für 0€ handeln | |||||
| 14.09. | Zeo ScientifiX, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 01.09. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.09. | Zeo ScientifiX, Inc.: ZEO ScientifiX Announces Multidisciplinary Expert Faculty Lineup for the ZEO Xperience | 220 | ACCESS Newswire | Leading physicians, scientists, regulatory experts, and healthcare innovators will convene October 23-25 at Fort Lauderdale's Pier Sixty-Six Resort + Marina for three days of regenerative medicine education... ► Artikel lesen | |
| 04.08. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.08. | Zeo ScientifiX, Inc.: ZEO ScientifiX Launches First-of-Its-Kind ZEO Xperience, a Three-Day Immersive Regenerative Medicine Experience for Healthcare Professionals | 228 | ACCESS Newswire | Hosted at Fort Lauderdale's newly reimagined Pier Sixty-Six Resort, the inaugural event combines cutting-edge biologics education, hands-on clinical training, practice growth strategies, and latest... ► Artikel lesen | |
| 24.07. | Zeo ScientifiX, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 21.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX Strengthens South Florida's Growing Biotechnology Ecosystem Through Regenerative Medicine Innovation | 311 | ACCESS Newswire | Operating from Nova Southeastern University's Center for Collaborative Research, ZEO ScientifiX is expanding physician education, scientific collaboration, and regenerative biologic innovation as Florida... ► Artikel lesen | |
| 08.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX Reports Strong Revenue Growth for Three Months and Six Months Ended April 30, 2026 | 354 | ACCESS Newswire | Company reports revenue growth of 124.6% for the quarter ended April 30, 2026 and 79.9% for the six months ended April 30, 2026, as compared to the same periods one year earlier as commercial momentum... ► Artikel lesen | |
| 01.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX to Host Live Educational Webinar for Healthcare Professionals Exploring the Southeast Regenerative Medicine Revolution | 406 | ACCESS Newswire | "One Year Later, Three States Stronger" program will examine lessons learned from Florida's first year into their pioneering stem cell law and provide physicians from other states an insight of what... ► Artikel lesen | |
| 16.06. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Zeo ScientifiX, Inc.: ZEO ScientifiX Donates Products to Support Pediatric Burn Reconstruction Mission in Peru | 238 | ACCESS Newswire | ZEO Medical Advisory Board Member Dr. Constantino Mendieta joins humanitarian effort providing reconstructive care to children recovering from severe burn injuries in Cusco, Peru DAVIE, FL / ACCESS... ► Artikel lesen | |
| 15.06. | Zeo ScientifiX, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.06. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.06. | Zeo ScientifiX, Inc.: ZEO ScientifiX Expands Medical Advisory Board with Leaders in Regenerative and Longevity Medicine | 502 | ACCESS Newswire | Company strengthens scientific leadership as regenerative medicine gains national momentum DAVIE, FL / ACCESS Newswire / June 9, 2026 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) ("ZEO ScientifiX" or the "Company")... ► Artikel lesen | |
| 27.05. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,695 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,280 | +2,54 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,885 | 0,00 % | Tempus verlängert Datenpartnerschaft mit Recursion bis 2029 | ||
| SUMMIT THERAPEUTICS | 16,985 | -4,87 % | UBS reiterates Summit Therapeutics stock rating on trial data | ||
| PRAXIS PRECISION MEDICINES | 299,90 | +0,21 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| MODERNA | 145,38 | +8,49 % | Moderna und BioNTech lassen Corona endgültig hinter sich | Aus dem alten Duell der beiden Corona-Gewinner ist ein neuer Wettbewerb geworden. Moderna erlebt nach überzeugenden Phase-3-Daten für eine personalisierte Krebstherapie eine spektakuläre Neubewertung.... ► Artikel lesen | |
| EVOTEC | 2,794 | +1,11 % | Evotec-Aktie +5%: Nur ein Strohfeuer oder der Beginn des Rebounds? | Die Kursentwicklung der Evotec-Aktie war zuletzt ein einziges Desaster. Innerhalb der letzten zwölf Monate halbierte sich der Kurs des Wirkstoffforschungsunternehmens und am Dienstag dieser Woche sackte... ► Artikel lesen | |
| CG ONCOLOGY | 77,15 | +3,35 % | CG Oncology auf Morgan Stanley Konferenz: Pläne für Markteinführung, Daten und Skalierung | ||
| ERASCA | 15,140 | +2,61 % | Propanc Biopharma, Inc.: Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. | ||
| BEAM THERAPEUTICS | 25,185 | +0,98 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| VERA THERAPEUTICS | 34,300 | +0,85 % | Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,500 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 39,600 | -2,00 % | Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday | ||
| ARCUTIS BIOTHERAPEUTICS | 25,630 | +1,02 % | Arcutis auf Morgan Stanley Konferenz: ZORYVE treibt Wachstumsoffensive voran | ||
| ABSCI | 9,600 | 0,00 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test |
Das Unternehmen ZEO SCIENTIFIX INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZEO SCIENTIFIX INC finden Sie auf Wallstreet Online.